NYSE:ABT
ABBOTT LABORATORIES
A diversified global healthcare giant delivering life-saving diagnostics, surgical instruments, and nutritional essentials with a strong cash-generating engine.
Key Metrics
Investment Thesis
Bull Case
Investors should consider Abbott for its defensive characteristics and consistent cash flow generation of over $6.5B annually, which supports a reliable dividend yield. The company's ability to innovate in high-margin segments like electrophysiology offers long-term growth potential that offsets slower growth in generic pharmaceuticals.
Bear Case
The stock faces valuation pressure as the 2024 net income spike of $13.4B appears anomalous compared to the more normalized $6.52B in 2025, raising concerns about earnings quality or one-time gains. Additionally, the substantial goodwill of $24.04B creates vulnerability to impairment charges if acquisition synergies fail to materialize as expected.
About ABBOTT LABORATORIES
Abbott Laboratories is a global healthcare leader serving patients in diagnostic, medical devices, nutritionals, and branded generic pharmaceuticals. The company leverages its diverse portfolio to deliver innovative solutions across hospitals, clinics, retail pharmacies, and home care settings worldwide.
Analysis
Management Discussion
Management successfully navigated a challenging macro environment to generate robust $9.57B in operating cash flow while maintaining a healthy balance sheet with $8.52B in cash equivalents. Despite a slight revenue contraction from 2024's peak, the company maintained profitability and returned significant capital to shareholders through dividends and buybacks.
Industry Overview
The global healthcare industry is undergoing a transformation driven by aging populations, technological advancements in precision medicine, and a shift toward value-based care models. Competition is fierce but consolidated companies like Abbott are well-positioned to capture market share through scale and innovation in diagnostics and devices.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $43.65B | $40.11B | $41.95B | $44.33B |
| Cost of Revenue | $19.14B | $17.98B | $18.71B | $19.32B |
| Gross Profit | $24.51B | $22.13B | $23.24B | $25.01B |
| Operating Expenses | $16.15B | $15.66B | $16.42B | $16.96B |
| Operating Income | $8.36B | $6.48B | $6.83B | $8.05B |
| R&D | $2.89B | $2.74B | $2.84B | $2.94B |
| G&A | $11.25B | $10.95B | $11.70B | $12.33B |
| Stock-Based Comp | $685.0M | $644.0M | $673.0M | $664.0M |
| Depreciation | $1.25B | $1.28B | $1.34B | $1.43B |
| Amortization | $2.01B | $1.97B | $1.88B | $1.68B |
| Other OpEx | $2.01B | $1.97B | $1.88B | $1.68B |
| Non-Operating Income | $-56.0M | $186.0M | $188.0M | $413.0M |
| Interest Expense | $558.0M | $637.0M | — | — |
| Interest Income | $183.0M | $385.0M | $344.0M | $308.0M |
| Pre-Tax Income | $8.31B | $6.66B | $7.01B | $8.47B |
| Income Tax | $1.37B | $941.0M | $-6.39B | $1.94B |
| Continuing Ops | $6.93B | $5.72B | $13.40B | $6.52B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $6.93B | $5.72B | $13.40B | $6.52B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $6.93B | $5.72B | $13.40B | $6.52B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $25.22B | $22.67B | $23.66B | $26.00B |
| Cash & Equivalents | $9.88B | $6.90B | $7.62B | $8.52B |
| Marketable Securities | $288.0M | $383.0M | $351.0M | $417.0M |
| Accounts Receivable | $6.22B | $6.57B | $6.92B | $7.93B |
| Inventory | $6.17B | $6.57B | $6.19B | $6.49B |
| Other Current Assets | $2.66B | $2.26B | $2.57B | $2.64B |
| Long-Term Assets | $49.21B | $50.54B | $57.76B | $60.72B |
| PP&E (Net) | $9.16B | $10.15B | $10.66B | $11.82B |
| Intangibles | $10.45B | $8.81B | $6.65B | $5.53B |
| Goodwill | $22.80B | $23.68B | $23.11B | $24.04B |
| Operating Leases | $1.12B | $1.12B | $1.07B | $1.13B |
| LT Investments | $766.0M | $799.0M | $886.0M | $918.0M |
| Other LT Assets | $4.75B | $5.83B | $15.24B | $17.16B |
| Total Assets | $74.44B | $73.21B | $81.41B | $86.71B |
| Current Liabilities | $15.49B | $13.84B | $14.16B | $16.50B |
| Current Debt | $2.25B | $1.08B | $1.50B | $3.03B |
| Current Leases | $230.0M | $245.0M | $254.0M | $276.0M |
| Taxes Payable | $343.0M | $492.0M | $594.0M | $569.0M |
| Other Current Liab | $11.78B | $11.07B | $10.79B | $11.52B |
| Long-Term Liabilities | $22.04B | $20.55B | $19.36B | $17.45B |
| Long-Term Debt | $14.52B | $13.60B | $12.62B | $9.90B |
| LT Operating Leases | $943.0M | $949.0M | $896.0M | $931.0M |
| Other LT Liab | $6.58B | $6.00B | $5.83B | $6.62B |
| Total Liabilities | $37.53B | $34.39B | $33.51B | $33.94B |
| Shareholders' Equity | $36.91B | $38.83B | $47.90B | $52.77B |
| Retained Earnings | $35.26B | $37.55B | $47.26B | $49.78B |
| AOCI | $-8.05B | $-7.84B | $-7.91B | $-6.00B |
| Total L&E | $74.44B | $73.21B | $81.41B | $86.71B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $6.93B | $5.72B | $13.40B | $6.52B |
| Non-Cash Adjustments | $1.05B | $1.75B | $1.28B | $341.0M |
| Working Capital Changes | $1.59B | $-215.0M | $-6.13B | $2.70B |
| Cash from Operations | $9.58B | $7.26B | $8.56B | $9.57B |
| Capital Expenditures | $1.78B | $2.20B | $2.21B | $2.17B |
| Cash from Investing | $-1.74B | $-3.13B | $-2.34B | $-2.42B |
| Share Buybacks | $3.79B | $1.23B | $1.29B | $893.0M |
| Dividends Paid | $3.31B | $3.56B | $3.84B | $4.12B |
| Cash from Financing | $-7.64B | $-7.09B | $-5.40B | $-6.31B |
| FX Effect | $-122.0M | $-23.0M | $-96.0M | $71.0M |
| Net Change in Cash | $83.0M | $-2.99B | $720.0M | $906.0M |
| Beginning Cash | $9.80B | $9.88B | $6.90B | $7.62B |
| Ending Cash | $9.88B | $6.90B | $7.62B | $8.52B |
Frequently Asked Questions
How does ABBOTT LABORATORIES make money?
The company operates through four primary segments: Diagnostic (laboratory equipment and in vitro diagnostics), Medical Devices (surgical instruments, electrophysiology, and heart failure devices), Nutritionals (formula-based and non-formula products for infants, adults, and clinical nutrition), and Established Pharmaceutical Products (branded generics including cardiovascular and respiratory therapies).
What are the main risks for ABT?
Regulatory headwinds and potential patent expirations on branded generics could impact future growth rates. Intense competition from larger tech firms entering medical devices and generic pharmaceuticals may pressure margins. Supply chain disruptions affecting raw materials for nutritionals or diagnostic reagents could lead to inventory volatility, as seen with the $195M inventory change.
What is ABT's competitive advantage?
Abbott benefits from a highly diversified revenue stream across four distinct healthcare sectors, providing stability against regulatory shifts in any single area. The company possesses deep R&D capabilities evidenced by its $2.94B annual investment and a dominant market position in high-growth categories like electrophysiology and surgical robotics.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.